Compare Bristol-Myers Squibb Co (BMY) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Micron Technology, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.85 (market cap $129.94B), while Micron Technology, Inc. trades at $925.01 (market cap $980.90B). The key difference: Micron Technology, Inc. is far larger — about 7.5× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | MU | |
|---|---|---|
Market Cap | $129.94B | $980.90B |
Sector | Health | Technology |
52-Week High | $65.89 | $1.21K |
52-Week Low | $42.60 | $115.79 |
Enterprise Value | $163.92B | $961.25B |
Dividend Yield | 3.96% | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Micron Technology (MU) trades at $925.24, up 7.46% with strong earnings momentum after beating Q1 2026 EPS estimates of $20.98 with $25.11. The stock shows bearish technical signals despite robust fundamentals including 55.91% net margin and 32.62% ROE. Recent news highlights AI-driven memory demand growth but concerns about cyclicality and competitive threats from new entrants like SpaceX's Terrafab facility.
Outlook remains positive with 81% analyst buy ratings and $1,540 consensus price target, though technical weakness and memory market cyclicality pose near-term risks. The company's strategic customer agreements provide revenue visibility through 2030, supporting long-term growth potential despite current bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
